Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- methyladenosine mRNA modification m6A tRNA snRNA gene obesity DNA ELISA dot blot 17341 IP immunoprecipitation
- Product Overview:
N6-Methyladenosine (m6A) is an abundant modification found in mRNA, tRNA, snRNA, as well as long non-coding RNA, in all species. RNA adenosine methylation is catalyzed by a multicomponent complex composed of METTL3/MT-A70, METTL14, and WTAP in mammals. METTL3 and METTL14 are responsible for the methyltransferase activity of the complex, and WTAP mediates substrate recruitment.{30057} The process shares similarities to histone methylation in that the modification is installed by m6A methylation “writers”, detected by methylation-specific “readers”, and can be reversed by demethylation “erasers”. The m6A modification has been shown to be conserved in the vicinity of stop codons and the 3’-untranslated region of specific mouse and human mRNAs.{25677} The process of regulating m6A modifications in mammalian mRNA has been linked to disease, where fat mass and obesity-associated (FTO) has been reported to be an obesity risk gene.{25677} FTO is an m6A demethylase and polymorphisms that result in increased FTO expression are associated with increased body mass and risk of obesity. Cayman’s N6-Methyladenosine Monoclonal Antibody (Clone 17-3-4-1) can be used for dot blot, ELISA, and immunoprecipitation applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.